AMA, AHA Call For Drug Pricing Transparency, Increased Competition
Published by Inside Health Policy
Representatives from the American Medical Association and the American Hospital Association called for increased drug pricing transparency and reduced regulations to increase competition at a panel on Monday (Sept. 25) on the cost of drugs at America’s Health Insurance Plans’ Medicare conference.
AMA Senior Vice President for Advocacy Richard Deem said that not much will change when it comes to rising costs until the industry achieves transparency in drug pricing.
“Physicians should be subject to transparency in terms to prices in health care, as should hospitals, as should PBMs as should pharmaceutical companies. Because right now it’s really hard. You can’t make good policy unless you have good data,” Deem said.
AHA Senior Vice President for Public Policy Ashley Thompson added that in order for there to be more transparency in drug pricing, more disclosure requirements should be tied to drug pricing and research and development when companies apply for drug approval.
Thompson also called for more competition and innovation. She said that AHA supports fast-tracking generic applications when no generic competition exists, incentivizing generic manufacturers with fast-track rewards, deeming pay-for-delay tactics to be presumptively illegal and increasing oversight of such agreements, and limiting the orphan drug incentive to true orphan drugs.
Deem expressed concern about laws and regulations used to stifle competition, such as use of the patent process or risk evaluation and mitigation strategies. AMA has called for an end to patent evergreening and recommended policy requiring a modest change in the product in order to extend the patent. He also said that the AMA wants FDA to minimize barriers for new products.
“We’ve got to continue to work together in this process. Health costs are a problem for the entire sector,” Deem said. “I think that those of us, whether it’s health plans, hospitals, physicians, drug-device manufacturers, we need to step up to the plate and own our part in the cost increase.” — Ariel Cohen
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
Senior Care Pharmacy Coalition Opposes CMS Final Rule on Minimum Staffing Standards for LTC Facilities
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy sector, released a statement today regarding its opposition to the Centers for Medicare & Medicaid Services (CMS) final rule on minimum staffing standards for long-term care (LTC) facilities.
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.